At one point after hours, Novavax (NASDAQ:NVAX) was down ~30% after STAT News reported that eight participants in a Phase 1 clinical trial evaluating COVID-19 vaccine candidate NVX-CoV2373 had to be hospitalized, a point later found to be erroneous. NVAX apparently contacted STAT to say that no subjects required hospitalization.
The stock is now down only 3% on turnover of 4.7M shares according to Nasdaq.